IRIS Institutional Research Information System - OPENBS Open Archive UniBS

GIACOMINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.176
EU - Europa 2.549
AS - Asia 2.300
SA - Sud America 474
Continente sconosciuto - Info sul continente non disponibili 189
AF - Africa 55
OC - Oceania 9
Totale 11.752
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.977
SG - Singapore 801
PL - Polonia 754
CN - Cina 691
IT - Italia 462
BR - Brasile 381
UA - Ucraina 309
DE - Germania 288
HK - Hong Kong 238
FI - Finlandia 187
VN - Vietnam 184
GB - Regno Unito 129
FR - Francia 97
CA - Canada 95
BD - Bangladesh 88
TR - Turchia 79
RU - Federazione Russa 73
IE - Irlanda 67
IN - India 64
SE - Svezia 38
AR - Argentina 32
NL - Olanda 29
JP - Giappone 26
MX - Messico 26
ID - Indonesia 25
ES - Italia 24
IQ - Iraq 23
CZ - Repubblica Ceca 22
BE - Belgio 19
ZA - Sudafrica 19
EC - Ecuador 17
TT - Trinidad e Tobago 15
CR - Costa Rica 13
VE - Venezuela 11
AT - Austria 10
JM - Giamaica 10
PK - Pakistan 10
SA - Arabia Saudita 10
CO - Colombia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
CL - Cile 7
MA - Marocco 7
NG - Nigeria 7
TN - Tunisia 7
EU - Europa 6
NI - Nicaragua 6
PE - Perù 6
UY - Uruguay 6
AU - Australia 5
EE - Estonia 5
GT - Guatemala 5
HN - Honduras 5
LT - Lituania 5
PH - Filippine 5
PY - Paraguay 5
TH - Thailandia 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CW - ???statistics.table.value.countryCode.CW??? 4
GP - Guadalupe 4
GR - Grecia 4
KE - Kenya 4
MY - Malesia 4
SV - El Salvador 4
EG - Egitto 3
GD - Grenada 3
HR - Croazia 3
JO - Giordania 3
KR - Corea 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PR - Porto Rico 3
BB - Barbados 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
GE - Georgia 2
IL - Israele 2
NZ - Nuova Zelanda 2
PA - Panama 2
PT - Portogallo 2
RO - Romania 2
ZM - Zambia 2
AG - Antigua e Barbuda 1
AO - Angola 1
BM - Bermuda 1
BO - Bolivia 1
BS - Bahamas 1
CU - Cuba 1
DK - Danimarca 1
GA - Gabon 1
HU - Ungheria 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
KI - Kiribati 1
Totale 11.560
Salva come PNG Salva come JPEG
Città #
Warsaw 749
Ashburn 678
Fairfield 543
Singapore 465
Woodbridge 335
San Jose 285
Hong Kong 238
Houston 225
Jacksonville 222
Cambridge 216
Seattle 192
The Dalles 189
Wilmington 184
Brescia 180
Chandler 170
New York 164
Council Bluffs 163
Beijing 160
Los Angeles 149
Ann Arbor 145
Helsinki 137
Princeton 116
Dallas 99
Munich 78
Dearborn 76
Dublin 65
Lauterbourg 62
San Francisco 62
Istanbul 58
Santa Clara 58
Chicago 57
Ho Chi Minh City 54
Nanjing 51
São Paulo 48
Orem 46
Denver 42
Hanoi 37
Montreal 36
Phoenix 36
Dong Ket 35
Des Moines 34
Redondo Beach 34
Atlanta 32
Buffalo 31
Columbus 30
Shanghai 29
San Diego 28
Milan 27
Brooklyn 26
London 26
Nanchang 25
Tokyo 23
Moscow 22
North Bergen 22
Boardman 21
Shenyang 21
Boston 20
Toronto 19
Turku 19
Brussels 18
Jakarta 18
Jinan 18
Brno 17
Amsterdam 16
Changsha 16
Chennai 16
Hebei 14
Guangzhou 13
Rio de Janeiro 13
Stockholm 13
Verona 13
Frankfurt am Main 12
Tianjin 12
Turin 12
Dhaka 11
Johannesburg 11
Tampa 11
Baghdad 10
Belo Horizonte 10
Jiaxing 10
Kocaeli 10
Lappeenranta 10
Manchester 10
Rome 10
San José 10
Charlotte 9
Naples 9
Queens 9
Washington 9
Chaguanas 8
Da Nang 8
Falkenstein 8
Hefei 8
Lanzhou 8
Mexico City 8
Nuremberg 8
Parma 8
Philadelphia 8
Raleigh 8
Tashkent 8
Totale 7.852
Salva come PNG Salva come JPEG
Nome #
Cannabidiol alters mitochondrial bioenergetics via VDAC1 and triggers cell death in hormone-refractory prostate cancer 915
Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease 408
U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis 354
Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. 318
A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers 312
Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors 303
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells. 257
Long pentraxin-3 follows and modulates bladder cancer progression 230
Long Pentraxin-3 As An Epithelial-Stromal Fibroblast Growth Factor-Targeting Inhibitor In Prostate Cancer. 216
Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. 212
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 207
The Antitumor Didox Acts as an Iron Chelator in Hepatocellular Carcinoma Cells 205
The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. 199
Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth 199
Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy 196
Antiangiogenic effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation. 192
Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach 190
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 183
Circulating microRNAs and Their Role in Multiple Myeloma 178
Long pentraxin 3: A novel multifaceted player in cancer 178
Stromal delivery of long Pentraxin-3 impairs FGF/FGFR-dependent tumor growth and metastasis 167
Future applications of FGF/FGFR inhibitors in cancer 166
Discovery of novel FGF trap small molecules endowed with anti-myeloma activity 161
Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy 159
Combining vascular disruption activity of TRAIL-expressing CD34+ cells with antiangiogenic activity of sorafenib improves regression of tumor growth 158
Inhibition of dna repair mechanisms and induction of apoptosis in triple negative breast cancer cells expressing the human herpesvirus 6 u94 158
β-Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease 153
Human CD34 + cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature 152
Hyperactive Akt1 Signaling Increases Tumor Progression and DNA Repair in Embryonal Rhabdomyosarcoma RD Line and Confers Susceptibility to Glycolysis and Mevalonate Pathway Inhibitors 152
The autocrine fgf/fgfr system in both skin and uveal melanoma: Fgf trapping as a possible therapeutic approach 151
FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer 148
(3)D [corrected] quantification of tumor vasculature in lymphoma xenografts in NOD/SCID mice allows to detect differences among vascular-targeted therapies 145
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments 145
Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease 144
sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib 144
Uptake Profiles of Human Serum Exosomes by Murine and Human Tumor Cells through Combined Use of Colloidal Nanoplasmonics and Flow Cytofluorimetric Analysis 142
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 140
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress 139
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 138
Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer 138
Halting the FGF/FGFR axis leads to anti-tumor activity in Waldenström's Macroglobulinemia by silencing MYD88 135
Potent in vivo anti-tumor activity of extracellular vesicles isolated from genetically engineered primary mesenchymal stromal cells expressing the trans-membrane TNF-Related Apoptosis-Inducing Ligand (TRAIL) 131
Stromal expression of long Pentraxin-3 impairs tumor growth and metastasis 128
Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma 128
Iron supplementation enhances RSL3-induced ferroptosis to treat naïve and prevent castration-resistant prostate cancer 124
The PTX3/TLR4 autocrine loop as a novel therapeutic target in triple negative breast cancer 121
Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model 120
Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors 118
Pentraxin 3 inhibits the angiogenic potential of multiple myeloma cells 118
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma 118
Glyco-Coated CdSe/ZnS Quantum Dots as Nanoprobes for Carbonic Anhydrase IX Imaging in Cancer Cells 114
PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma 113
Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress 113
FGF-trapping hampers cancer stem-like cells in uveal melanoma 111
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma 109
β-Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism 108
The FGF/FGFR System in the Physiopathology of the Prostate Gland 106
The histone deacetylase inhibitor ITF2357 (Givinostat) promotes Burkitt’s lymphoma cell line death modulating micro-RNA and Tissue Transglutaminase 2 expression 104
Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited anti-tumor activity 101
Design, synthesis, in vitro and in vivo biological evaluation of 2-amino-3-aroylbenzo[b]furan derivatives as highly potent tubulin polymerization inhibitors 98
Post-transplant evaluation of bone marrow hematopoietic function in patients receiving high-dose Yttrium-90-Ibritumomab Tiuxetan (Zevalin) with autograft 97
Human CD34+ Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Exert a Potent Anti-Lymphoma Effects by Targeting Tumor Vasculature 94
Proteasome inhibitors as anticancer agents 86
FGF/FGFR inhibitors downmodulates c-Myc oncoprotein and hampers the growth of adrenocortical carcinoma 86
The natural FGF-trap long pentraxin 3 inhibits lymphangiogenesis and lymphatic dissemination 85
An ureido-substituted benzenesulfonamide carbonic anhydrase inhibitor exerts a potent antitumor effect in vitro and in vivo 85
Turn-Adopting Peptidomimetic as a Formyl Peptide Receptor-1 Antagonist 81
The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients 78
Targeting TRAIL Receptors with Genetically-Engineered CD34+ Hematopoietic Stem Cells 78
Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma 73
Preclinical Rationale for the Use of the Multikinase Inhibitor Sorafenib in the Treatment of Human Lymphomas 71
Monoclonal antibodies for targeted treatment of lymphoproliferative neoplasias 49
Cancer Stem-like Cells: a new therapeutic target for the treatment of metastatic uveal melanoma 19
Totale 11.752
Salva come PNG Salva come JPEG
Categoria #
all - tutte 51.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 51.115
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022447 0 0 0 21 20 40 38 42 16 74 46 150
2022/2023497 80 15 29 29 43 120 6 51 68 1 37 18
2023/2024615 42 13 96 27 20 101 22 26 125 24 17 102
2024/20251.351 21 23 14 198 131 140 118 81 146 88 229 162
2025/20263.244 303 369 202 421 344 230 458 120 160 262 140 235
2026/20271.491 708 139 200 444 0 0 0 0 0 0 0 0
Totale 11.752